Document:

Exhibit

PERSONAL & CONFIDENTIAL

	
		
	Date:
	[Date]

	To:
	[Executive]

	From:
	[Name]

	 
	[Title]

    
Subject:    Rogers Corporation Severance Plan Participation Agreement

I am pleased to advise that you have been designated as an “Eligible Employee” for the purposes of the Rogers Corporation Severance Plan, as amended from time to time (the “Plan”).  A copy of the current plan document is enclosed).

This means that, upon your execution of this agreement, you will be eligible to receive the severance benefits described in the Plan in the event you experience a “Qualifying Termination” as defined under the Plan; provided, however, that your “Severance Coverage Period” for purposes of the Plan shall be [•] months, except that, if you incur a Qualifying Termination during the [•]-year period after a “Change in Control” as defined under the Plan, your Severance Coverage Period shall be [•] months. If you have any questions please contact me or [name], [title].

By signing the attached signature page and in consideration of the opportunity to participate in the Plan, you agree to be bound by the terms of the Plan, including the covenants set forth in Section 5 of the Plan. Your participation in the Plan does not confer any rights to continue in the employ of Rogers Corporation or any of the affiliates.  You are hereby notified that you may be entitled to immunity from liability for certain disclosures of trade secrets under the Defend Trade Secrets Act, 18 U.S.C. § 1833(b).

Please sign the attached signature page and return the original to me as soon as possible.

Best regards,

[name]
[title]

Rogers Corporation Severance Plan 
Agreement Signature Page

[date]

I, [name], have read the Rogers Corporation Severance Plan and agree to its terms, and I agree to be bound by the terms of the covenants in Section 5 of the Plan.  This agreement supersedes any and all prior agreements and communications, whether written or oral, between the Company and me regarding the subject matter of the Plan.

	
			
	Signature
	 
	Date

Return to [name] [title] by [date].Exhibit

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Exhibit 10.52

AMENDMENT 2 TO WAFER SUPPLY AGREEMENT

This Amendment number 2 (the “Amendment”) is effective as of September 1, 2018 and  amends the Wafer Supply Agreement that is effective as of October 1, 2010, as amended by Amendment Number 1 that is effective as of January 1, 2014 (the Wafer Supply Agreement and Amendment Number 1 together “the AGREEMENT”), and is entered into by and between:
		
	(1)
	Power Integrations International, Ltd., a Cayman Islands corporation having its principal place of business at 4th Floor, Century Yard, Cricket Square, Elgin Avenue, P.O. Box 32322, Grand Cayman  KY1-1209 (“POWER INTEGRATIONS”); and

		
	(1)
	X-FAB Semiconductor Foundries GmbH (formerly known as, and successor in interest of X-FAB Semiconductor Foundries AG) having its principal place of business at Haarbergstrasse 67, 99097 Erfurt, Germany (“COMPANY”).

RECITALS
WHEREAS, the parties to this Amendment hereby agree to amend the AGREEMENT; and
WHEREAS, in accordance with Section 18.10 of the AGREEMENT, the AGREEMENT may be amended only by an instrument in writing duly executed by an authorized representative of COMPANY and POWER INTEGRATIONS.
NOW THEREFORE, the parties agree as follows:

AMENDMENT
I.     Addition of section B-2 to Exhibit B. 

II.    Section 10.4 is amended by the following:
The actual amount of the [*] paid by PI and received by X-FAB Texas is [*]

III.    A new section 10.6 is created with the following:
		
	10.6
	As of [*], PI owns the [*]tool as well as the[*] valued together at [*]thus [*]cost to [*] to be [*]

IV.    Section 13.1 of the AGREEMENT is amended as follows:
		
	13.1
	The AGREEMENT shall continue in full force and effect from the Effective Date until [*] unless earlier terminated as provided herein (“Term”).

V.    Section 19.1 is deleted in its entirety and replaced with:
		
	19.1
	Subject to the prior written approval of PI, X-FAB Texas will [*] (1) the following [*], which is, (a) [*], (b) [*], (c) [*] (d) [*] (e) [*] and (f) [*] ((a) through (f) collectively the[*]); (2) the installation of the [*]; and (3) the fitting for the [*].  X-FAB Texas will be responsible for the cost of items 2 and 3. Subject to PI’s prior written approval of the specific [*] manufacturers, model numbers, and purchase price (the “ [*]”), PI will reimburse X-FAB Texas for the [*]Cost in accordance with Sections 10.4 and 10.5.

VI.        The exclusivity period as specified in Section 19.10 as being [*] is replaced with [*].

VII.    A new Section 19.11 is added to Article 19 as follows:
		
	19.11
	During the course of manufacturing of [*]and in order to fulfill the production volume demand, additional [*]may become necessary. Subject to PI’s prior written approval of the specific [*]manufacturers, model numbers, and the price of the additional [*], X‐FAB shall purchase and own such additional [*] and PI shall provide the funds for such[*] to be added to the[*]Cost and to be[*] as defined in Sections 10.4 and 10.5. 

[SIGNATURE ON NEXT PAGE]

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed in their respective corporate names by their duly authorized representatives on the date written below.
	
		
	X-FAB Semiconductor Foundries GmbH
	Power Integrations International, Ltd.

	Signature: /s/ Loyd L. Whetzel
	Signature: /s/ Raja Petrakian

	Title: CEO/President: X-FAB Texas, Inc.
	Title: President and Director

	Date: 1/24/2019
	Date: 1/24/2019

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Exhibit B-2
PRICES for X-FAB [*] WAFERS

[*] WAFER ([*])
Price:                   [*]            [*]                  [*]

Delivery times: To be agreed after [*] of [*] WAFERS            

                                
[*] WAFER
Price: [*]

Delivery times: To be agreed after [*] of [*] WAFERS                                            
                        

MASK TOOLING SET 
Price:                        [*]        [*]                        

[ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.Exhibit 10.1

 

JOINT VENTURE AGREEMENT

 

THIS JOINT VENTURE
AGREEMENT (this "Agreement"), is entered into this 07 day of February, 2019, by and between Cannabics Pharmaceuticals,
Inc., a Nevada corporation with an address at #3 Bethesda Metro Center, Suite 700 Bethesda, MD 20814 ("Cannabics"),
and Wize Pharma, Inc., a Delaware corporation with an address at 24 Hanagar Street, PO Box 6653, Hod Hasharon,
Israel ("Wize"), (Cannabics and Wize, each a "Founder", and collectively, the "Founders").

 

WHEREAS, the
Founders are interested in incorporating a joint venture company under the laws of Israel for the purpose of researching, developing,
and administering cannabinoid formulations to treat ophthalmic conditions (the "Business"); and

 

WHEREAS, the
Founders desire to set forth in writing certain agreements as hereinafter described regarding the establishment of the joint venture
company and the rights and obligations of the Founders;

 

NOW, THEREFORE,
in consideration of the mutual promises hereinafter contained, the Parties hereto agree as follows:

 

1.       Establishment
of the Company

 

1.1       Incorporation
of the Company. The Founders will establish a private company incorporated in Israel, with the name of "WPCP Pharma"
or any other similar name lawfully available (the "Company"). The Founders will file the required documents to
establish the Company within 14 days (as may be extended by mutual written consent) following the Effective Date (as defined below).
Cannabics (the "Incorporator") shall be responsible for incorporating the Company. The shares of the Company shall
have such rights and restrictions as set forth in the Charter Documents (as defined below), as may be amended from time to time.

 

1.2       Incorporation
Documents. The shares of the Company shall have such rights and restrictions as set forth in the Charter Documents, as may
be amended from time to time.

 

1.3       Ratification
of Actions Taken Prior to Incorporation. The Company shall ratify the activities of the Incorporator as the incorporator of
the Company.

 

1.4       Founder
Representations/Undertakings. Each Founder represents that neither the execution nor the performance of this Agreement violates
any agreement to which he is bound or any provisions of applicable law. Each Founder further agrees to notify the Company immediately
if any conflict with its performance of this Agreement arises. Each Founder agrees to execute any further documents or instruments
reasonably necessary to carry out the purposes or intent of this Agreement. Notwithstanding anything to the contrary in this Agreement,
the Founders agree and acknowledge the following:

 

 

 

    	 	1	 

     

    

 

1.4.1 All of the activities
of the Business shall be carried out according to each Founder's respective territorial, regulatory and commercial restrictions,
as existing on the date hereof.

 

1.4.2 Without derogating
from the generality of the foregoing, and for the sake of clarity, nothing herein will require Wize to take any action that is
inconsistent or in conflict with its obligations under the Exclusive Distribution and Licensing Agreement with Resdevco Ltd., dated
as of May 1, 2015, as amended and supplemented thereafter.

 

2.              
Shareholdings 

 

2.1       Initial
Shareholding. The issued share capital of the Company upon its incorporation shall be as follows:

 

	Shareholder	Ordinary Shares	Shareholding Percentage
	Cannabics	50,000	50%
	Wize	50,000	50%
	Total:	100,000	100%

 

 

3.              
Obligations of the Founders

 

3.1       Notwithstanding anything to the contrary hereunder,
each Founder has, and shall retain, the sole and exclusive ownership of all right, title, and interest in and to its intellectual
property, including any and all developments, modifications, enhancements, improvements, and derivative works made thereto, and
including all patents, copyrights, and other intellectual property rights associated therewith.

 

3.2       Each Founder acknowledges and agrees that, subject to
Section 3.3 below, title to, and all rights and interest in, all materials, products and deliverables prepared by such Founder
in the performance of services for the Company (whether prior to or subsequent to its incorporation), including, but not limited
to, reports, designs, programs, specifications, documentation, manuals, visual aids, software programs, and any other materials
developed and/or prepared by such Founder for the Company (collectively, "Work Product"), in each case, if and
to the extent such services are to be performed by such Founder shall vest in the Company and shall be deemed to be work made
for hire, unless otherwise mutually agreed in writing (such as where the parties agree that performance of services will result
in a limited non-exclusive license for use solely in the Business). To that end, (i) to the extent that any such Work Product
may not be considered work made for hire, each Founder hereby irrevocably assigns all right, title and interest therein to the
Company without further consideration, and (ii) all such materials shall belong exclusively to the Company, with the Company having
the right to obtain and to hold in its own name, copyrights, trademarks, patents, registrations or such other protection as may
be appropriate to the subject matter, and any extensions and renewals thereof.

 

 

 

    	 	2	 

     

    

 

4.       Business and
Management of the Company

 

4.1       Business
of the Company. The Company will engage in all business activities permitted under relevant law; provided, however, that the
Company will focus on the Business.

 

4.2       Business
Plan. Promptly following the Effective Date, the Founders will work together to prepare a mutually acceptable business plan,
which will be completed no later than 30 days after the Effective Date and shall include its initial budget as well as the respective
contribution, if any, of each Founder's cash, non-cash assets and/or services to the Company (the "Business Plan"),
as such plan may be revised by the Company's Board of Directors (the "Board") from time to time. Prior to
the execution of the Business Plan, the Founders will conduct a freedom to operate analysis. The Company will conduct its business
in accordance with the Business Plan.

 

4.3       Budget.
At the beginning of each calendar year after incorporation of the Company, the Company shall prepare a budget for the upcoming
calendar year of operations, the approval of which will be subject to the consent of the Company's Board of Directors

 

4.4       "Board
of Directors". The Company's initial Board shall be comprised of three (3) directors. The Founders, for as long as such
Founder owns at least ten percent (10%) of the issued and outstanding shares of the Company, will each be entitled to recommend
and appoint one director, and the third director shall be an industry expert recommended by Wize and approved by Cannabics. Each
Founder shall be entitled to remove the director appointed by such Founder and appoint a new director instead, at any time, upon
prior written notice to the Company.

 

4.5       Officers.
The initial officers of the Company shall be Noam Danenberg, and Eyal Barad, who shall serve as Co-Chief Executive Officers.

 

4.6       Signatory
Authority. The Board will decide on an appropriate signatory authority for the Company in light of the operational needs of
the Company.

 

4.7       Expenses.
Until the Company has a revenue stream or as may otherwise be determined in the Business Plan, each Founder shall be
responsible for fifty percent (50%) of the expenses of the Company, including the incorporation costs and associated legal
fees.

 

4.8       Information
Rights. The Charter Documents shall provide for information rights to the Founders, such that, except as necessary to comply
with applicable law or contract and subject to any applicable privileges (including the attorney-client privilege), each Founder,
for as long as it holds at least five percent (5%) of the outstanding shares of the Company, will be given reasonable access to
the Company's employees, agents, properties, books and records for all proper purposes, during normal business hours and upon reasonable
prior notice, the costs of review of which, if any, shall be borne by each Founder seeking to review the same. The Company will
prepare and deliver such financial or other information concerning its business as a Founder may reasonably request, provided that
if the Founder making such request holds less than 5% of the outstanding shares of the Company, the expenses associated therewith
will be borne by such Founder (other than with respect to annual and quarterly financial statements of the Company).

 

 

 

    	 	3	 

     

    

 

4.9       Veto
Rights. The Charter Documents shall provide as for veto rights to the Founders, such that, for as long as a Founder holds at
least ten percent (10%) of the outstanding shares of the Company, the Company shall not undertake any of the following actions
without first obtaining the prior written consent of the directors appointed by such Founder: (a) a merger, consolidation, or sale
of all or substantially all of the Company's assets or shares (other than as part of a drag-along transaction pursuant to Section
7); (b) a liquidation, dissolution, or winding up of the Company or the termination of the Company's activities; (c) a fundamental
change in the nature of the Company's business; (d) any amendment to the Articles of Association of the Company that adversely
effects the rights of such Founder (it being understood that amendments associated with the issuance of shares as part of a financing
shall not be deemed an adverse change); (e) the issuance of any shares, options to acquire shares, or debt securities of the Company;
(f) an increase in the number of directors of the Company to more than three (except in connection with a financing (g) any appointment
or removal of an executive officer of the Company; (h) a transfer, assignment or exclusive license of any intellectual property
that is fundamental to the operation of the Business to any third party (other than as part of a drag-along transaction pursuant
to Section 7); and (i) any "related party transaction" (as shall be defined in the Charter Documents or pursuant to applicable
law).

 

4.10 Necessary Actions.
The Founders will act in such a manner as may be necessary to give effect to the provisions of this Agreement, including appointing
or removing directors, as provided above, causing such directors to give effect to such provisions, and causing its shares to be
voted at a general meeting of shareholders to give effect to such provisions.

 

5.       Restrictions
on Share Transfers.

 

5.1       Permitted
Transfers. Each Founder may, at any time, transfer all or part of its shares in the Company ("Shares") to
an Affiliate (as defined below), provided that at the time of such transfer such transferee will execute such instruments as may,
in the Company's reasonable opinion, be necessary to ensure that (a) such transferee has acceded to be bound by all of the terms
of this Agreement, and (b) the Founder remains responsible for such transferee's performance of its obligations hereunder; and
further provided that such transfer shall remain valid for only so long as such Affiliate remains an Affiliate of the Founder.
Thereafter any reference in this Agreement to a Founder's shareholdings shall include all Shares held by such Founder and its authorized
transferees pursuant to this Section 5.1. Any change in the relationship of the Affiliate holding an interest in Company and such
Founder, such that the Affiliate ceases to be an Affiliate, shall obligate such Founder promptly to re-acquire the Shares from
such Affiliate. "Affiliate" means, with respect to any person, any other person directly and/or indirectly controlling,
directly and/or indirectly controlled by, or under direct and/or indirect common control with, such person.

 

 

 

 

    	 	4	 

     

    

 

5.2       Right of First
Refusal 

 

Until the closing of
a Company Sale or an IPO (as such terms are defined below), each Founder for so long as it holds at least ten percent (10%) of
the issued and outstanding shares of the Company (a "Qualified Founder") shall be entitled to a right of first
refusal on all transfers of Shares by the other Founder. No Founder shall sell, assign, charge (other than creation of a lien pursuant
to Section 5.2.5 below) or transfer (together, "Transfer") all or any of the Shares owned by such Founder except
as set forth below (and except for the permitted transfer of Shares to an Affiliate under Section 5.1 above):

 

5.2.1 In the event a
Founder (the "Offeror") proposes to Transfer any of his Shares (the "Offered Shares") to any
person or entity (the "Proposed Transfer"), the Offeror shall promptly request (the "Offeror's Request")
that the Company deliver to the other Founder, provided that the other Founder is a Qualified Founder, a written notice containing
the identity of the proposed transferee, the number of Shares included in the Proposed Transfer, and the terms and conditions concluded
in good faith of the Proposed Transfer (the "Offeror's Notice"), so as to enable the other Founder to have the
opportunity to exercise their right of first refusal pursuant to this Section 5.2. The Company shall comply with the Offeror's
Request by sending the Offeror's Notice to the other Founder.

 

5.2.2 The Qualified Founder
shall have the right to purchase all (and not less than all) of the Offered Shares pursuant to the terms of the Offeror's Notice
by sending a written notice (the "Acceptance Notice") to the Company within thirty (30) days from receipt of the
Offeror's Notice (the "Notice Period").

 

5.2.3 If the Acceptance
Notice is in respect of less than the number of Offered Shares or is not timely provided, then the Offeror shall be entitled to
Transfer all (but not less than all) of the Offered Shares to the proposed transferee; provided, however, that in no event shall
the Offeror Transfer any of the Offered Shares to any transferee on terms more favorable to the transferee than those mentioned
in the Offeror's Notice, and provided, further, that such Transfer must be closed within 120 days after the expiration of the Notice
Period or the Proposed Transfer shall again be subject to the provisions of this Section 5.2.

 

5.2.5 Should a Founder
create a lien on his Shares, such Founder shall be obligated to inform the beneficiary of the lien of the existence of the right
of first refusal and that any exercise of the lien shall be deemed a Transfer which is subject to the provisions of this Section
5.2.

 

5.2.6 "Company
Sale" means a merger, business combination, sale of shares or any other similar transaction involving the Company, in
which the shareholders of the Company immediately prior to the merger, business combination or other similar transaction will own,
as a result of which and immediately after the consummation (including all stages) thereof, less than the majority of shares of
the surviving entity; in each case, whether as one transaction or a series of related transactions. "IPO" means
an initial public offering of the shares of the Company.

 

 

 

    	 	5	 

     

    

 

6.                  
Co-Sale/Tag-Along Right.

 

6.1       Until the
closing of a Company Sale or an IPO, subject at all times to the provisions of Section 5.2 (Right of First Refusal) above, in
the event of any Proposed Transfer by a Founder, other than a permitted transfer of Shares pursuant to Section 5.1 above, each
Qualified Founder shall have the right, within fourteen (14) days after receipt of the Offeror's Notice, to participate pro-rata
in the Proposed Transfer by sending the Acceptance Notice, in which it shall designate how many shares it wishes to sell up to
its pro-rata share. Each participating Qualified Founder's pro-rata co-sale right shall be expressed by a fraction, the numerator
of which is the number of outstanding shares of the Company then held by the Founder, and the denominator of which is the sum
of (i) the aggregate number of shares of the Company then held by all the shareholders of the Company exercising co-sale rights,
plus (ii) the aggregate number of outstanding shares of the Company then held by the Offeror, multiplied by 100. If a Founder
does not respond to the Offeror's Notice within the aforesaid time period, it shall be deemed to have waived its right to participate
in such Transfer.

 

6.2       If the
Acceptance Notice is not timely provided, then the Offeror shall be entitled to Transfer all (but not less than all) of the Offered
Shares to the proposed transferee; provided, however, that in no event shall the Offeror Transfer any of the Offered Shares to
any transferee on terms more favorable to the transferee than those mentioned in the Offeror's Notice, and provided, further,
that such Transfer must be closed within 120 days after the expiration of the Notice Period or the Proposed Transfer shall again
be subject to the provisions of this Section 6.

 

7.                  
Compulsory Sale - Drag-Along.

 

7.1       In the
event that prior to an IPO, any person or entity (the "Bidder") makes a bona fide offer to acquire or purchase
(i) all of the issued share capital of the Company or (ii) all or substantially all of the Company's assets (the "Offered
Transaction"), and shareholders holding at least 75% of the issued share capital of the Company indicate their acceptance
of the Offered Transaction (the "Majority Selling Shareholders"), and the Offered Transaction is approved by
a majority of the Board, then the Company shall deliver notice thereof to all shareholders (the "Drag-Along Notice")
and each shareholder will (a) vote its shares in the Company in favor of the Offered Transaction and any decision necessary
therefor (including the appointment of a representative of the Majority Selling Shareholders as proxy on its behalf for all matters
reasonably necessary for the Offered Transaction and the implementation thereof) at every meeting called with respect thereof
or any matters pertaining thereto, (ii) exercise their means of control in the Company in order for the Company to execute all
necessary agreements and documents and to take all such actions reasonably required for the approval and implementation of the
Offered Transaction, (iii) execute all necessary agreements and documents and take all such actions as may be reasonably required
in connection therewith, and (iv) sell all its shares and other securities in accordance with the terms of the Offered Transaction;
provided, however that if the Offered Transaction is not consummated within a period of 180 days after the date of the
Drag-Along Notice, the Offered Transaction shall once again be subject to the terms of this Section.

 

 

 

    	 	6	 

     

    

 

7.2       Each
shareholder shall appear in person or by proxy at any annual or special general meeting for the purpose of obtaining a quorum and
shall vote its shares, either in person or by proxy, at any annual or special meeting called for the purpose of voting on the Offered
Transaction or any matter reasonably related thereto (including appointment of a representative appointed by the Majority Selling
Shareholders as proxy on their behalf for all matters reasonably necessary for the transaction and the implementation thereof)
or by written consent of shareholders with respect to the Offered Transaction, in favor of the Offered Transaction and any decision
necessary therefor (including the appointment of a representative appointed by the Majority Selling Shareholders as proxy on their
behalf for all matters reasonably necessary for the transaction and the implementation thereof) in accordance with this Section
7. Without limitation of the foregoing, upon a failure by a shareholder to comply with this Section 7, such shareholder hereby
irrevocably appoints any designee nominated from time to time by the Board to execute on behalf of such shareholder any and all
documents, instruments, deeds and agreements that are required to be executed by the shareholders pursuant to this Section 7.

 

7.3       Notwithstanding
the foregoing, a shareholder will not be required to comply with the provisions of Sections 7.1 and 7.2 unless: (i) the liability
for indemnification, if any, of such shareholder in the Offered Transaction and for the inaccuracy of any representations and warranties
made by the Company or its shareholders in connection therewith is several and not joint with any other person who is not an Affiliate
of such shareholder (except to the extent that funds may be paid out of an escrow established to cover breach of representations,
warranties and covenants of the Company as well as breach by any shareholder of any of identical representations, warranties and
covenants provided by all shareholders), and is pro rata in proportion to, and does not exceed, the amount of consideration payable
to such shareholder in connection with such Offered Transaction; and (ii) upon the consummation of the Offered Transaction, each
shareholder will receive the same form of consideration and the same portion of the aggregate consideration that such shareholder
would have received if such aggregate consideration (whether in the form of cash, securities or otherwise) had been distributed
by the Company in complete liquidation pursuant to the rights and preferences set forth in the Charter Documents as in effect immediately
prior to such transaction.

 

8.       Pre-Emptive Right

 

Until an IPO or Company
Sale, each shareholder holding at least 5% of the outstanding share capital of the Company (a "Qualified Shareholder")
shall have a pre-emptive right to purchase New Securities (as defined in Section 8.1) that the Company may, from time to time,
propose to sell and issue.

 

8.1       In
this Section 8, "New Securities" shall mean any shares of the Company, whether now or hereafter authorized,
and rights, options, convertible instruments or warrants to purchase said shares, and securities of any type whatsoever that
are, or may become, convertible into said shares, other than (i) employee stock options and employee share grants under the
Company's equity incentive plans; (ii) issuances of Company securities in connection with a bona fide loan or credit facility
of a third party financial lender; (iii) issuance of Company securities in an IPO of the Company; (iv) issuances of Company
securities pursuant to an acquisition by the Company of another company or business; (v) issuances of Company securities in
connection with any pro rata stock splits, dividends, distributions, combinations, reclassifications or similar events; and
(vi) issuances exempted from preemptive rights if approved by the shareholders owning at least 75% if the outstanding shares
of the Company.

 

 

 

    	 	7	 

     

    

 

8.2       Any
New Securities to be issued by the Company shall first be offered by the Board by written notice of offer to the Qualified
Shareholders (the "Rights Notice") pro rata to their respective holdings then held by them as of the
date of the Rights Notice. Such Rights Notice shall state the terms, including without limitation the price per share, of the
proposed allotment, and any such shareholder may accept such offer, as to all or any part of the shares so offered to him, by
giving the Company written notice of acceptance within twenty (20) days after being served with the Rights Notice and
effecting full payment therefore thereafter. Any of the New Securities which a Qualified Shareholder fails or declines to
acquire as aforesaid shall be reoffered, in the manner prescribed in the foregoing provisions of this Section 8.2, to the
other Qualified Shareholders who submitted notices of acceptance as to all the New Securities initially offered to them
pursuant hereto, in proportion to their respective shareholdings. Even if the Qualified Shareholders who elect to purchase
New Securities elect to purchase in the aggregate less than 100% of the New Securities, the New Securities so elected to be
purchased shall be sold to such shareholders in accordance with such elections.

 

8.3       Any
of the New Securities which are not accepted by the Qualified Shareholders as aforesaid may be subsequently allotted without
restriction, but only on terms no more favorable to the allottee than the terms offered to the Qualified Shareholders. Any of
the New Securities not so allotted within ninety (90) days from the expiration of the re-offer described above shall again be
subject to all the provisions of this Section 8.

 

9.                  
Effective Date 

 

This Agreement shall
become effective on the date (the "Effective Date") that is one business day following receipt of an opinion, within
30 days from the date of signing, from a mutually selected third party describing the regulatory pathway for eye drops containing
cannabinoids or cannabinoid strings (the "Opinion"). If the Opinion is not received within 30 days of the date hereof,
this Agreement shall become null and void unless otherwise extended by mutual agreement of the parties.

 

10.               
Mutual Share Issuances

 

10.1 Upon
the Effective Date (i) Wize shall issue to Cannabics 900,000 shares of its common stock (the "Wize Shares"), which
represent a value of $909,933, calculated using a price per share equal to the weighted-average price per share of its
common stock as traded during the sixty-day period ending on February 5, 2019 (the "60-Day VWAP"), and (ii)
Cannabics shall issue to Wize 2,263,944 shares of its common stock (the "Cannabics Shares" and together with
the Wize Shares, the "Restricted Shares"), which represent a value of equals of $909,933, calculated using a
price per share equal to the weighted-average price per share of its common stock as traded during the sixty-day period
ending on February 5, 2019. All of these issued Restricted Shares shall be free of free of any mortgage, pledge, lien,
royalty obligations, conditional sale agreement, security agreement, encumbrance or other charge (collectively, "Liens"), subject
to any restrictions on transfer under applicable securities Laws and this Agreement. Notwithstanding the above, the Founders
are committed to share and provide the necessary cash payments for any of the Company's operations as per the Business Plan
within 3 days of the Company's demand for such cash request.

 

 

 

    	 	8	 

     

    

 

10.2 The Restricted
Shares Are Not Registered. Each of the Founders hereby acknowledges that the Restricted Shares will not be issued by the Founders
pursuant to a registration statement under the Securities Act, and therefore they may be required to be held for an indeterminate
period. The Restricted Shares are issued in reliance upon a specific exemption from the registration requirement of the Securities
Act which depends, in part, upon the accuracy of the representations, warranties, and agreements of each Founder set forth in this
Section 10.

 

10.3 Representations of the Founders.

 

10.3.1 Each Founder is
acquiring the applicable Restricted Shares for such Founder's own account as principal, not as a nominee or agent, for investment
purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof, in whole or in part, which resale,
distribution or fractionalization would violate the Securities Act. Each Founder agrees that a legend to the foregoing effect may
be placed upon any and all certificates issued representing the Restricted Shares. Further, each Founder does not have any contract,
undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third
person, with respect to the Restricted Shares.

 

10.3.2 Each Founder is
sophisticated and experienced in investment matters, and, as a result, is in a position to evaluate an investment in the other
Founder. Each Founder is aware that an investment in the other Founder involves a high degree of risk, may result in a lack liquidity,
and places substantial restrictions on transferability of interest. Each Founder has sufficient financial resources available to
support the loss of all or a portion of the value of the Restricted Shares, has no need for liquidity in connection with the Restricted
Shares, and is able to bear the economic risk of such investment.

 

11.               
[RESERVED]

 

12.               
Confidentiality

 

12.1 Each Founder agrees
to maintain in confidence and trust, and not disclose or make any unauthorized use of, whether for his own personal benefit or
for the benefit of others, any proprietary or confidential information of the Company, including without limitation, trade secrets,
know-how, business plans, and marketing plans, whether documentary, written, oral or computer generated. The Company's confidential
information does not include information that is now, or hereafter becomes, through no act or failure to act on the part of a Founder,
generally known to the public or information which is generally known in the trade or industry, which is not gained as result of
a breach of this Agreement.

 

 

 

    	 	9	 

     

    

 

12.2 Press Release.
Neither Founder shall issue any press release or public announcement concerning this Agreement or the Company without obtaining
the prior written consent of the other Founder hereto, which consent shall not be unreasonably withheld, except as may be required
by applicable securities laws, in which case, the publishing Founder shall use reasonable commercial efforts to send the draft
public announcement to the other Founder prior to publication thereof.

 

13.               
Non-Compete, Non-Solicitation and Right Of First Refusal.

 

13.1 For so long as
Cannabics either (a) performs services for the Company or (b) holds at least five percent (5%) of the shares of the Company, Cannabics
shall refrain from developing, investing in (other than through its holding of the Wize Shares issued hereunder), promoting, or
selling any ophthalmology product.

 

13.3 For so long as
Wize either (a) performs services for the Company or (b) holds at least five percent (5%) of the shares of the Company, Wize shall
refrain from developing, investing in (other than through its holding of the Cannabics Shares issued hereunder), promoting, or
selling any cannabis-based products.

 

13.4 Subject to non
compete clause section 13.1 and 13.2 above, in case the Company decided for any reason not to invest in a new venture relating
any ophthalmology or cannabis-based products which was proposed to the Company by any of the Founders, the Company will have 10%
of the said venture without the need to invest funds.

 

13.5 Notwithstanding
the above, sections 13.1 to 13.3 shall not apply to minority stakes and/or passive investment and /or non controlling equity held
by either company in competitive projects.

 

14.               
Governing Law and Dispute Resolution

 

This Agreement shall
be governed by and construed in accordance with the laws of Israel without reference to its conflict of laws principles. Any dispute
arising hereunder shall be referred to the competent courts in Tel Aviv.

 

15.               
Miscellaneous 

 

15.1 Entire Agreement.
This Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement and supersedes
all prior agreements, understandings, and negotiations, both written and oral, between the parties with respect to the subject
matter hereof or thereof, including the Memorandum of Understanding, dated June 20, 2018.

 

 

 

    	 	10	 

     

    

 

15.2 Amendments.
Any provision of this Agreement may be amended if, and only if, such amendment is in writing and signed by all parties hereto.

 

15.3 No Waivers.
No failure or delay by a Founder in exercising any right or remedy under this Agreement shall operate as a waiver thereof, nor
shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right
or remedy.

 

15.4 Assignment.
No Founder may assign this Agreement nor his rights or obligations hereunder without the prior written consent of the other Founder,
except to its Affiliates (for as long as they continue to be its Affiliates and subject to Section 5.1 above).

 

15.5 Successors
and Assigns. The provisions of this Agreement shall be binding upon and inure to the benefit of the Founders and their respective
successors and permitted assigns.

 

15.6 Severability.
In the event that any provision of this Agreement shall be determined to be illegal or unenforceable, that provision will be limited
or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable.

 

15.7 Counterparts.
This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the
signatures to each were upon the same instrument.

 

15.8 No Third Party
Beneficiaries. The parties agree that there are no third party beneficiaries to this Agreement.

 

15.9 Acceptance
by the Company. The Founders will procure endorsement of this Agreement by the Company as soon as it is formed, signifying
the Company's agreement with, and acceptance of, the Agreement's terms insofar as they affect the Company.

 

15.10 Termination.
If, for whatever reason, the Founders do not approve the Business Plan by June 30, 2019, this Agreement shall expire at such time,
and the Founders shall cooperate in winding down the Company.

 

[signature page follows]

 

 

 

    	 	11	 

     

    

 

IN WITNESS
WHEREOF, the parties have executed this Agreement as of the day first above written.

 

 

	Cannabics Pharmaceuticals, Inc.	Wize Pharma, Inc.
	 	 
	/s/ Eyal Barad	/s/ Or Eisenberg
	Name: Eyal Barad	Name: Or Eisenberg
	Title: CEO	Title: CFO & Acting CEO
	Date:February 7, 2019	Date: February 7, 2019

 

 

 

 

 

 

 

 

 

 

 

 

    	 	12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]